Diallyl Trisulfide
(Synonyms: 二烯丙基三硫化物) 目录号 : GC43439
Diallyl Trisulfide是一种从大蒜中提取的有机硫化合物。
Cas No.:2050-87-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Diallyl Trisulfide is an organosulfur compound derived from garlic [1]. Diallyl Trisulfide increases reactive oxygen species (ROS) in cancer cells, leading to oxidative stress and consequently cell cycle arrest (particularly at the G2/M phase) [2]. Diallyl Trisulfide inhibits tumor migration, invasion, and angiogenesis, and may also modulate signaling pathways such as MAPK, STAT3, PKC-δ, and Nrf2/Akt [3]. Diallyl Trisulfide is primarily used to treat gastric, breast, and prostate cancers [4].
In human primary colorectal cancer cells, Diallyl Trisulfide (0-40μM; 24h) reduces cell viability [5]. In colo 205 cells, Diallyl Trisulfide (0-50μM; 24h) reduces cell viability [6].
In diabetic mice ischemia model, Diallyl Trisulfide (500μg/kg; ip; 14d) significantly improved the more severe tissue damage and vascular dysfunction in diabetic mice during ischemic injury [7]. In CT-26 cells xenograft mice model, treatment with Diallyl Trisulfide (10mg/kg, 50mg/kg; ip; 4 weeks) resulted in a decrease in tumor volume and weight [8].
References:
[1]. Liang D, Wu H, Wong M W, et al. Diallyl trisulfide is a fast H2S donor, but diallyl disulfide is a slow one: the reaction pathways and intermediates of glutathione with polysulfides[J]. Organic letters, 2015, 17(17): 4196-4199.
[2]. Na H K, Kim E H, Choi M A, et al. Diallyl trisulfide induces apoptosis in human breast cancer cells through ROS-mediated activation of JNK and AP-1[J]. Biochemical pharmacology, 2012, 84(10): 1241-1250.
[3]. Guo X, Su B. Diallyl Trisulfide Intervention in Redox Homeostasis and Its Multitarget Antitumor Effects[J]. Journal of Agricultural and Food Chemistry, 2025.
[4]. Lu L, Gao Z, Song J, et al. The potential of diallyl trisulfide for cancer prevention and treatment, with mechanism insights[J]. Frontiers in Cell and Developmental Biology, 2024, 12: 1450836.
[5]. Yu C S, Huang A C, Lai K C, et al. Diallyl trisulfide induces apoptosis in human primary colorectal cancer cells[J]. Oncology reports, 2012, 28(3): 949-954.
[6]. Lai K C, Hsu S C, Kuo C L, et al. Diallyl sulfide, diallyl disulfide, and diallyl trisulfide inhibit migration and invasion in human colon cancer colo 205 cells through the inhibition of matrix metalloproteinase‐2,‐7, and‐9 expressions[J]. Environmental toxicology, 2013, 28(9): 479-488.
[7]. Yang H B, Liu H M, Yan J C, et al. Effect of diallyl trisulfide on ischemic tissue injury and revascularization in a diabetic mouse model[J]. Journal of Cardiovascular Pharmacology, 2018, 71(6): 367-374.
[8]. Wu P P, Liu K C, Huang W W, et al. Diallyl trisulfide (DATS) inhibits mouse colon tumor in mouse CT-26 cells allograft model in vivo[J]. Phytomedicine, 2011, 18(8-9): 672-676.
Diallyl Trisulfide是一种从大蒜中提取的有机硫化合物 [1]。Diallyl Trisulfide会增加癌细胞中的活性氧（ROS），导致氧化应激，从而导致细胞周期停滞（尤其是在G2/M期） [2]。Diallyl Trisulfide可抑制肿瘤迁移、侵袭和血管生成，并可能调节MAPK、STAT3、PKC-δ和Nrf2/Akt等信号通路 [3]。二烯丙基三硫化物主要用于治疗胃癌、乳腺癌和前列腺癌 [4]。
在人类原发性结直肠癌细胞中，Diallyl Trisulfide（0-40μM；24h）会降低细胞活力 [5]。在Colo 205细胞中，Diallyl Trisulfide（0-50μM；24h）会降低细胞活力 [6]。
在糖尿病小鼠缺血模型中，Diallyl Trisulfide（500μg/kg；ip；14d）显著改善了糖尿病小鼠缺血性损伤过程中较严重的组织损伤和血管功能障碍 [7]。在CT-26细胞异种移植小鼠模型中，Diallyl Trisulfide（10mg/kg，50mg/kg；ip；4周）治疗导致肿瘤体积和重量减小 [8]。
| Cell experiment [1]: | |
Cell lines | Human primary colorectal cancer cells |
Preparation Method | Human primary colorectal cancer cells were seeded onto 96-well plates at 1×104 cells/well 24h before treatment. The cultures were then rinsed in phenol-free RPMI-1640 medium and incubated with the Diallyl Trisulfide at the final concentrations 0, 10, 20 and 40μM in RPMI-1640 culture medium for 24h. At the end of incubation, 20μL of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (5mg/mL) was added to each well and incubated for 4h at 37℃ then the MTT solution was removed and 200μL dimethylsulfoxide (DMSO) was added to dissolve the crystals. The absorbance of each well at 570nm was measured by using a spectrophotometric plate reader. |
Reaction Conditions | 0-40μM; 24h |
Applications | Diallyl Trisulfide reduces cell viability. |
| Animal experiment [2]: | |
Animal models | Diabetic mice ischemia model |
Preparation Method | Mice were injected intraperitoneally (ip) with streptozotocin (STZ); 200mg/kg, dissolved in vehicle (0.1mol/L sodium citrate buffer, pH 4.5) or citrate buffer (control). Blood glucose was measured 72 hours after injection. Mice with blood glucose levels < 300mg/dL were injected again with STZ (100mg/kg). Four days after the second STZ injection, blood glucose was measured again. Mice with blood glucose levels > 300mg/dL were considered diabetic. Briefly, two weeks after successful induction of diabetes, the left femoral artery (between the proximal inguinal ligament and the distal popliteal fossa) was ligated and transected under anesthesia (chloral hydrate, 400mg/kg, ip) to produce a severe ischemic model. After induction of ischemia, all animals were randomly divided into four groups of 12: a non-diabetic group treated with Diallyl Trisulfide (or untreated) and a diabetic group treated with DATS (or untreated). The Diallyl Trisulfide treatment group received intraperitoneal injection of 500μg/kg daily for 14 consecutive days starting from the day of ischemia induction. |
Dosage form | 500μg/kg; ip; 14d |
Applications | Diallyl Trisulfide significantly improved the more severe tissue damage and vascular dysfunction in diabetic mice during ischemic injury. |
References: | |
| Cas No. | 2050-87-5 | SDF | |
| 别名 | 二烯丙基三硫化物 | ||
| Canonical SMILES | C=CCSSSCC=C | ||
| 分子式 | C6H10S3 | 分子量 | 178.3 |
| 溶解度 | DMF: 10 mg/ml,DMF:PBS (pH 7.2) (1:4): 0.2 mg/ml,DMSO: 5 mg/ml,Ethanol: 3 mg/ml | 储存条件 | Store at 2-8°C,stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.6085 mL | 28.0426 mL | 56.0852 mL |
| 5 mM | 1.1217 mL | 5.6085 mL | 11.217 mL |
| 10 mM | 560.9 μL | 2.8043 mL | 5.6085 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet